MOTS-c: what the FDA has and hasn’t decided

MOTS-c is not FDA-approved, and as of Oct 27, 2026 a licensed pharmacy may not compound it. FDA advisers voted 7 to 5 in July 2026 to recommend letting pharmacies make it for obesity and osteoporosis, but the FDA’s own review found no human studies of it at all, and the agency has not acted on the vote. This guide explains what MOTS-c is, what the research covers, why clinics sell it, and what would have to happen before it could be prescribed. It covers status only, not dosing.

What MOTS-c is

MOTS-c is short for “mitochondrial open reading frame of the 12S rRNA type-c”. Mitochondria, the energy-producing parts of cells, carry their own small set of DNA. In 2015, researchers at the University of Southern California reported that a short stretch of it, inside the gene for a ribosomal RNA called 12S, encodes a 16-amino-acid peptide, which they named MOTS-c (Lee 2015). It circulates naturally in the blood of people and rodents.

The MOTS-c sold online is a lab-made copy, as a free base or an acetate salt. The FDA notes that the one nomination to compound it gave inconsistent information about which of the two it meant (FDA briefing).

What the research covers

All of the published research on what MOTS-c does comes from animals and cells.

• The 2015 discovery paper. It studied cells and mice, and measured insulin sensitivity, weight gain on a high-fat diet and age-related insulin resistance in mice given MOTS-c (Lee 2015).
• Later animal and cell studies. According to the FDA, they looked at glucose and fat metabolism, bone formation and breakdown, and calcium build-up in blood vessels, in rodents and in lab-grown cells. The FDA says these studies were “restricted to rodent models” and did not test how effects change with dose, and that the molecule MOTS-c acts on is still unknown.
• A lab study in human blood. Researchers incubated MOTS-c in human blood and found it was broken down quickly. The FDA says this “raises the question as to whether exogenous administration of MOTS-c to humans can generate pharmacologically active concentrations of the peptide over time.”
• People. The FDA searched PubMed, Embase, ClinicalTrials.gov and its adverse event database. It found no clinical studies or human exposure data for MOTS-c by any route of administration, and no toxicity studies in animals either.

A result in mice is a starting point for research, not evidence about people, and no trial has tested MOTS-c for weight, bone, muscle, energy or aging in humans.

Why clinics market it

The FDA’s review found websites claiming that MOTS-c regulates mitochondrial energy, improves glucose control, protects against insulin resistance, promotes weight loss, improves physical performance, supports muscle health and slows cellular aging. One holistic clinic said it works with compounding pharmacies to get MOTS-c, and a wellness clinic offered it in an IV “cocktail”. Outsourcing facilities reported compounding no MOTS-c products from January 2017 through December 2025 (FDA briefing).

None of those claims comes from a human study. They extend findings in mice and cells.

Where MOTS-c stands with the FDA

How compounding works, and why MOTS-c doesn’t qualify

Under section 503A, a pharmacy may compound from a bulk ingredient only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or is on the 503A bulks list. While the FDA builds that list, it allows compounding with substances in its Category 1 that were nominated before Jan 7, 2025 (FDA interim policy). The FDA states that there is no monograph for MOTS-c and that it is not a component of an approved drug, and its categories list, updated May 14, 2026, does not place it in Category 1 (FDA).

The FDA’s review

Wells Pharmacy Network nominated MOTS-c for compounding and later withdrew the nomination; the FDA’s safety page lists it among substances previously in Category 2, its safety-risk list, that their nominators withdrew. The FDA evaluated MOTS-c anyway, on its own initiative. It concluded that “the physicochemical characterization, information on historical use, lack of any safety and effectiveness information in humans” weigh against adding it, and proposed “not adding MOTS-c (free base) or MOTS-c acetate to the 503A Bulks List” (FDA briefing). Its safety page says the FDA “has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration” and “lacks important information regarding any safety issues raised by MOTs-C” (FDA).

The July 2026 vote

The Pharmacy Compounding Advisory Committee took up MOTS-c on July 23, 2026, for obesity and osteoporosis (Federal Register). The FDA has not posted minutes or official vote counts (FDA). According to a law firm that followed the meeting, MOTS-c was recommended “with seven votes for ‘yes,’ five votes for ‘no,’ and two votes in abstention”, and FDA scientists had recommended against each peptide reviewed (McDermott). The same day, the committee also recommended BPC-157, KPV and TB-500.

What has to happen next

An advisory committee advises; it doesn’t decide. To put MOTS-c on the bulks list, the FDA would have to publish a proposed rule in the Federal Register, take public comments and issue a final rule. As of Oct 27, 2026, it has not published a proposed rule. The same law firm expects rulemaking could happen in 2027 or take several years.

If the FDA does add MOTS-c, a licensed 503A pharmacy could compound it for an individual prescription. It still would not be an FDA-approved drug: the FDA would not have reviewed it for safety or effectiveness, and its use for weight, energy or aging would remain untested in human trials.

Sport and controlled-substance status

WADA’s 2026 Prohibited List names MOTS-c in class S4.4.1, metabolic modulators, as an activator of the enzyme AMPK, banned at all times (WADA). It is not on the DEA’s list of controlled substances, dated Oct 21, 2026 (DEA). Not being controlled doesn’t make it legal to sell as a drug.

What about vials labeled for research?

MOTS-c is widely sold online in vials labeled for laboratory research. Buying these to inject is unsafe and unregulated. No prescriber decides whether it suits you, no licensed pharmacy answers for what is in the vial, and no one has checked its identity, strength or sterility. The FDA has no human data on any form of it. If a website offers you a “prescription” for compounded MOTS-c today, it is offering something a licensed pharmacy may not lawfully make. Our guide on whether peptides are safe covers how to check a provider.

If you are interested in what it is marketed for

The FDA’s review notes that there are FDA-approved drugs for weight reduction in obesity and for osteoporosis, the two uses its advisers considered. For weight, our guide to peptides vs GLP-1 medications compares the approved peptide drugs, and the weight loss hub explains how prescriptions work online. No drug is FDA-approved to treat aging itself; our guide on whether longevity medicine is legit looks at what longevity clinics offer.

The bottom line

MOTS-c is a real peptide made in human cells, and the research on giving it as a drug is in mice, rats and cells. The FDA found no human studies, proposed keeping it off the compounding list, and has not acted on its advisers’ 7 to 5 vote to recommend it. As of Oct 27, 2026 there is no lawful prescription source, and WADA bans it. We’ll update this page if the FDA publishes a proposed rule. For every other peptide, see are peptides legal in 2026 or the peptides hub.